Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users

Running, not enrolling

Conditions studied: Schizophrenia

In brief

This study uses existing health records and insurance claims data to understand how adults in the United States are treated with KarXT, a medication for schizophrenia. It will describe who receives KarXT, how it is used in real-world practice, and how often healthcare services such as hospital visits are used. It will also explore information recorded by clinicians about schizophrenia symptoms

Key facts

Study ID

NCT07571148

Run by

Bristol-Myers Squibb

People needed

6876

Starts

2026-01-16

Expected to finish

2026-07-31

Last updated by the study team

2026-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants in the Veradigm EHR/claims-linked database with evidence of treatment with KarXT on or after September 24, 2024
• Earliest KarXT treatment date = index date
• Aged 18 years or older on index date

You may not qualify if…

• Not applicable

Where it is running

• Veradigm — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.